Citations (19)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Carmine Salerni, Andrea Baccelli, Elena M. Parazzini, Rocco Rinaldo & Stefano Centanni. (2024) A tailored approach to refractory severe Mepolizumab-associated headache: a case study. Journal of Asthma 61:6, pages 649-652.
Read now
Read now
Andreas Schneider, Reto Jost, Christoph Jordi & Jakob Lange. (2023) Autoinjectors for large-volume subcutaneous drug delivery: a review of current research and future directions. Expert Opinion on Drug Delivery 20:6, pages 815-830.
Read now
Read now
Laren D Tan, Nolan Nguyen, Abdullah Alismail & Mario Castro. (2022) Management of Uncontrolled Asthma: A Framework for Novel and Legacy Biologic Treatments. Journal of Asthma and Allergy 15, pages 875-883.
Read now
Read now
Bruce C. Roberts, Christopher Rini, Rick Klug, Douglas B. Sherman, Didier Morel & Ronald J. Pettis. (2022) Novel cannula design improves large volume auto-injection rates for high viscosity solutions. Drug Delivery 29:1, pages 43-51.
Read now
Read now
Michelle Dilley Revier & Bob Geng. (2022) Mepolizumab prefilled syringe for the treatment of severe eosinophilic asthma: focus on the pediatric population. Expert Review of Respiratory Medicine 16:8, pages 857-865.
Read now
Read now
Francesco Menzella, Matteo Fontana, Patrizia Ruggiero, Francesco Livrieri & Nicola Facciolongo. (2022) Home-based treatment of biologics for asthma: who, what, where, when and why. Expert Review of Respiratory Medicine 16:4, pages 419-428.
Read now
Read now
Reika Miyokawa, Celeste Kivler, Samuel Louie, Dorottya Godor, Laren Tan & Nicholas Kenyon. (2020) Self-Administered Mepolizumab in the Management of Severe Asthma: Usability and Patient Acceptance. Patient Preference and Adherence 14, pages 1669-1682.
Read now
Read now
Georgios Hillas, Evangelia Fouka & Andriana I Papaioannou. (2020) Antibodies targeting the interleukin-5 signaling pathway used as add-on therapy for patients with severe eosinophilic asthma: a review of the mechanism of action, efficacy, and safety of the subcutaneously administered agents, mepolizumab and benralizumab. Expert Review of Respiratory Medicine 14:4, pages 353-365.
Read now
Read now
Andreas Schneider, Philippe Mueller, Christoph Jordi, Philipp Richard, Peter Sneeringer, Ranjan Nayyar, Mary Yovanoff & Jakob Lange. (2020) Hold the device against the skin: the impact of injection duration on user’s force for handheld autoinjectors. Expert Opinion on Drug Delivery 17:2, pages 225-236.
Read now
Read now
Articles from other publishers (10)
Francesco MENZELLA, Carlo LOMBARDI & Marcello COTTINI. (2024) Self-administration of biologicals for severe asthma: insights for clinicians. Minerva Respiratory Medicine 63:1.
Crossref
Crossref
Yoni E. van Dijk, Niels W. Rutjes, Korneliusz Golebski, Havva Şahin, Simone Hashimoto, Anke-Hilse Maitland-van der Zee & Susanne J. H. Vijverberg. (2023) Developments in the Management of Severe Asthma in Children and Adolescents: Focus on Dupilumab and Tezepelumab. Pediatric Drugs 25:6, pages 677-693.
Crossref
Crossref
Timothy G. Chow, John Oppenheimer & Shyam R. Joshi. (2022) A Review of Adverse Reactions to Biologics Used in Allergy-Immunology Practice. The Journal of Allergy and Clinical Immunology: In Practice 10:12, pages 3075-3086.
Crossref
Crossref
Timothy G. Chow, Lauren E. Franzblau & David A. Khan. (2022) Adverse Reactions to Biologic Medications Used in Allergy and Immunology Diseases. Current Allergy and Asthma Reports 22:12, pages 195-207.
Crossref
Crossref
Oliver William Massey & Cenk Suphioglu. (2022) Taking a Breather: Advances in Interleukin 5 Inhibition for Asthma Relief. International Journal of Molecular Sciences 23:19, pages 11166.
Crossref
Crossref
Alida Benfante, Stefania Principe, Maria Noemi Cicero, Maria Incandela, Gabriele Seminara, Carmen Durante & Nicola Scichilone. (2022) Management of severe asthma during the first lockdown phase of SARS-CoV-2 pandemic: Tips for facing the second wave. Pulmonary Pharmacology & Therapeutics 73-74, pages 102083.
Crossref
Crossref
Roy M. Fleischmann, Amy E. Bock, Wuyan Zhang, Charles M. Godfrey, Ivana Vranic, Carol Cronenberger & Eva Dokoupilová. (2022) Usability Study of PF-06410293, an Adalimumab Biosimilar, by Prefilled Pen: Open-Label, Single-Arm, Sub-Study of a Phase 3 Trial in Patients with Rheumatoid Arthritis. Rheumatology and Therapy 9:3, pages 839-850.
Crossref
Crossref
S.A. Bendien, M.M. van Leeuwen, H.S. Lau, A. Ten Brinke, L.E. Visser, E.M. de Koning & G.J. Braunstahl. (2022) Home-based intravenous treatment with reslizumab for severe asthma in the Netherlands – An evaluation. Respiratory Medicine 194, pages 106776.
Crossref
Crossref
Ian D. Pavord, Andrew Menzies-Gow, Roland Buhl, Pascal Chanez, Mark Dransfield, Njira Lugogo, Oliver N. Keene, Eric S. Bradford & Steve W. Yancey. (2021) Clinical Development of Mepolizumab for the Treatment of Severe Eosinophilic Asthma: On the Path to Personalized Medicine. The Journal of Allergy and Clinical Immunology: In Practice 9:3, pages 1121-1132.e7.
Crossref
Crossref
Young-A Heo. (2020) Mepolizumab prefilled syringe and autoinjector: a profile of their use in severe eosinophilic asthma. Drugs & Therapy Perspectives 36:4, pages 131-138.
Crossref
Crossref